



## Krystal Biotech to Report Second Quarter 2026 Financial Results on August 3, 2026

July 23, 2026

PITTSBURGH, July 23, 2026 (GLOBE NEWSWIRE) -- [Krystal Biotech, Inc.](#) (the "Company") (NASDAQ: KRY5) announced today that it will report its second quarter 2026 financial results on Monday, August 3, 2026, prior to the open of U.S. markets.

The Company's management will also host a conference call and webcast at 8:30 am ET on Monday, August 3, 2026, to discuss the financial results and provide a business update.

Investors and the general public can access the live webcast at: <https://www.webcaster5.com/Webcast/Page/3018/54300>.

For those unable to listen to the live webcast, a replay will be available for at least 30 days on the Investors section of the Company's website at [www.krystalbio.com](http://www.krystalbio.com).

### About Krystal Biotech, Inc.

Krystal Biotech, Inc. (NASDAQ: KRY5) is a fully integrated, commercial-stage, global biotechnology company focused on the discovery, development and commercialization of genetic medicines to treat diseases with high unmet medical needs. VYJUVEK<sup>®</sup>, the Company's first commercial product, is the first-ever redosable gene therapy and the first genetic medicine approved in the United States, Europe, and Japan for the treatment of dystrophic epidermolysis bullosa. The Company is rapidly advancing a robust preclinical and clinical pipeline of investigational genetic medicines. Krystal Biotech is headquartered in Pittsburgh, Pennsylvania. Visit [www.krystalbio.com](http://www.krystalbio.com) to learn more or follow us on [LinkedIn](#) and [X](#).

### CONTACT

#### Investors and Media:

Stéphane Paquette, PhD

Krystal Biotech

[spaquette@krystalbio.com](mailto:spaquette@krystalbio.com)

